Positioning political buying, disclosed 2026-08-18
Options no verdict drawn today, left as found
Ethical passes the values gate
Price44.98 USD
Fair value67.78
Ethical score86.9/100
RatingOPPORTUNITY
Our investment reviews on this name
2026-08-28Read Markup49.37-8.9% to today
2026-07-03Read Distribution48.55-7.4% to today ✓
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Boston Scientific holds its Distribution at $44.98. Elevated stress, defensive posture warranted, held for 8 days.
As held on the ledger · 2026-09-08
Phase
Distribution · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 8 days
Price at the screen
$44.98
Valuation
18.21 trailing · 13.09 forward price to earnings
Values screen
PASS· score 86.9
Beta
0.57
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
26.19%
Below 33%
Interest-bearing debt is just 26.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
11.20%
Below 49%
Money owed to the company is 11.2% of assets, under the 49% limit.
Pass
Revenue purity
0.14%
Below 5%
Only 0.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OPPORTUNITY: it trades at roughly a 51% discount to our $67.78 fair value, moderate competitive moat, 7.50% revenue growth.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 50.7% margin of safety to the base estimate.
Third-party analyst targets: 29 covering, consensus Buy. The average target sits +33% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
The quiet tools fixing hearts in operating rooms
When a cardiologist threads a stent through a blocked artery in Boston or Berlin, Boston Scientific makes the device that gets the job done. The firm builds tools for heart and digestive procedures in two focused divisions. It stands out because revenue climbs 12 percent a year, margins sit at 17 percent, and the shares trade at just 11.9 times forward earnings against a fair value that implies 72 percent upside.
Return on equity reaches 15 percent with a moderate moat and a clean ethical pass. Twenty-eight analysts carry a strong buy rating with a 70 dollar median target. The business grows steadily in a defensive sector where demand rarely vanishes.
Regulation, hospital budget cuts and rival devices remain real threats that could test pricing power. Currency swings add another layer in markets outside the United States. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BSX trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-28Markup · changed$49.37+11.6%Entry 11
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (32 analysts) rates it strong buy, with a mean price target of $83.
2026-07-28Distribution$44.25+0.0%Entry 10
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (32 analysts) rates it strong buy, with a mean price target of $83. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-27Distribution$44.25+0.0%Entry 9
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (32 analysts) rates it strong buy, with a mean price target of $83. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-26Distribution$44.25+0.0%Entry 8
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (32 analysts) rates it strong buy, with a mean price target of $83. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-25Distribution$44.25+0.5%Entry 7
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 0.5% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (32 analysts) rates it strong buy, with a mean price target of $83. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-24Distribution$44.03+0.0%Entry 6
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (32 analysts) rates it strong buy, with a mean price target of $83. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-23Distribution$44.03+0.0%Entry 5
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (32 analysts) rates it strong buy, with a mean price target of $83. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-22Distribution$44.03-9.3%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 9.3% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (32 analysts) rates it strong buy, with a mean price target of $83. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Distribution$48.55+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (32 analysts) rates it strong buy, with a mean price target of $83.
2026-07-03Distribution$48.55+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
